Retinal Rejuvenation – Naturally, from Ellex

A non-thermal laser therapy, Retinal Rejuvenation Therapy (2RT™) stimulates a natural, biological healing response in the eye and in a pilot study on 50 patients has demonstrated potential as an intervention which may positively influence early Age-Related Macular Degeneration (AMD). Clinical studies have also shown 2RT™ to be an effective treatment for Clinically Significant Macular Edema (CSME).

Clinical and scientific studies have demonstrated the ability of 2RT™ to improve retinal function and to halt or delay the degenerative processes that cause some retinal diseases. Specifically, in the pilot study 2RT™ has been shown to reduce the area and volume of drusen from a baseline of 5% or more, and to deliver a functional improvement in some high-risk early AMD patients.

Unlike conventional retinal laser therapy, which can cause permanent collateral damage to the sensitive structures of the eye, 2RT™ protects the retina from thermal damage. It also offers the potential to apply treatment earlier in the disease process with the aim of slowing retinal degeneration, thereby eliminating or delaying the risk of vision-threatening complications associated with the late-stage of retinal disease.

Nanosecond Laser Technology

2RT™ utilizes solid-state, nanosecond laser technology delivered through a patented speckled beam profile. This breakthrough treatment approach selectively targets individual cells within the RPE in order to induce a therapeutic effect without causing permanent collateral damage.

2RT for Early AMD

To date, 2RT™ is the only treatment option in patients with early Age-Related Macular Degeneration (AMD) where it can produce bilateral improvements in macular function and appearance and function. Conventional AMD treatments, such as ongoing intraocular injections of anti-vascular endothelial growth factor (anti-VEGF) medications, address late-stage complications associated with the disease.

In contrast, 2RT™ could offer the potential to apply treatment earlier in the disease process and to intervene at the level of the underlying pathology, preventing neovascularization and the progression to wet AMD. With 2RT™, we aim to treat the causes of the disease before vision loss occurs. A large randomized clinical trial of 2RT laser is currently underway to determine long term effects of the laser and what benefits it might offer.

2RT_drusen

2RT for CSME

Clinical studies have shown 2RT™ to be as effective as retinal photocoagulation in reducing cystoid macular edema secondary to diabetic retinopathy. Unlike retinal photocoagulation, which results in localized destruction of photoreceptors, edema and architectural loss to overall tissue, 2RT™ protects the photoreceptors, and therefore retinal function, from thermal damage. It also uses approximately 500 times less energy than retinal photocoagulation: the huge reduction in radiant exposure proportionately reduces the risk of damage to all aspects of retinal function.

  1. Guymer, R.H., et al., Nanosecond-laser application in intermediate 
AMD – 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol. 2013 Oct 3. doi: 10.1111/ceo.12247)
  2. I. Jobling et al., “Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage,” The FASEB Journal 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.
  3. Casson RJ. Et al., Pilot Randomised trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema, Clinical and Experimental Ophthalmology 2012; 40: 604-610